Key result
Herpes zoster vaccination is linked to an ~18% lower risk of stroke and MI.
Why the study?
Does herpes zoster vaccination reduce cardiovascular events in adults aged ≥18 years?
Meta-Analysis
Yes
Does herpes zoster vaccination reduce cardiovascular events in adults aged ≥18 years?
Answers are grounded in this paper and cite their sources.
Herpes zoster vaccination is associated with an approximately 18% reduction in the risk of stroke and myocardial infarction in adults, suggesting a potential cardioprotective effect.
Background Numerous studies have indicated an increased risk of stroke and myocardial infarction (MI) following herpes zoster (HZ); however, the impact of vaccination remains uncertain [1-4]. Purpose To assess HZ vaccination effectiveness with recombinant zoster vaccine (RZV) or zoster vaccine live-attenuated (ZVL), against cardiovascular (CV) events (stroke, MI, or CV death) in adults aged ≥18 years and ≥50 years. Methods A global systematic literature review (Medline, Embase, Lilacs; 2004–2024) and meta-analysis were conducted of phase 3 randomized controlled trials (RCTs) and observational studies assessing the effect of HZ vaccination on CV events. Meta-analysis inclusion criteria followed Cochrane guidelines [5]. Heterogeneity of included studies was examined by the I 2 index. Pooled risk ratio (RR) and 95% confidence interval (CI) were estimated with random-effects models. Results 19 studies were included in the review; eight observational studies and one RCT met the meta-analysis inclusion criteria for HZ vaccination effectiveness on CV events [6-14]. Across all nine studies, 53.32% of participants were male. Seven studies reported mean ages from 53.6 years [6] to 74.0 years [13]. No studies assessed CV deaths. Any HZ vaccination (RZV or ZVL) was associated with a significantly lower risk of stroke and MI, versus no HZ vaccination: pooled RR of 0.82 (95% CI 0.76–0.87) in adults ≥18 years and RR of 0.84 (0.82–0.87) in adults ≥50 years. Thus, vaccine effectiveness was 18% (13–24%) and 16% (13–18%) in preventing CV events, respectively (Figure 1). RZV vaccination was associated with a significantly lower risk of stroke and MI versus no HZ vaccination: pooled RR 0.79 (0.65–0.97) in adults ≥18 years and RR 0.79 (0.64–0.97) in adults ≥50 years, with a vaccine effectiveness of 21% (3–35%) and 21% (3–36%), respectively (Figure 2). Conclusions HZ vaccination (ZVL or RZV) was associated with a significantly lower rate of CV events. The potential cardioprotective effect of HZ vaccination could help to further reduce disease burden in adults, warranting further research.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2025) conducted a meta-analysis in Cardiovascular events (stroke, myocardial infarction, or cardiovascular death). Herpes zoster vaccination (RZV or ZVL) vs. No herpes zoster vaccination was evaluated on Stroke and myocardial infarction (RR 0.82, 95% CI 0.76-0.87). Herpes zoster vaccination was associated with a lower risk of stroke and myocardial infarction compared to no vaccination in adults ≥18 years.
Synapse has enriched 10 related papers. Consider them for comparative context: